These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2004-001103-35 Exemestane in Advanced or Recurrent Endometrial Carcinoma. A multicentre non-randomized Phase II study not-yet-due
Exempt 2004-001356-37 Phase I-II-III studies of Cisplatin and Combretastatin (CA4P) in recurrent or advanced servical cancer not-yet-due
Ongoing 2004-002429-37 A randomized trial of adjuvant treatment with radiation plus chemotherapy versus radiation alone in high-risk endometrial carcinoma NSGO-EC-9501 Amendment 2. not-yet-due
Ongoing 2004-005218-35 A phase II study of management of the patients with locally advanced (FIGO III & IVa or stage II unfavorably located lesion) or relapsed vulvar carcinoma not-yet-due
Ongoing 2014-004269-26 Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal ca... not-yet-due
Ongoing 2016-000193-38 ENGOT-EN1/FANDANGO: A randomized phase II trial of first-line combination chemotherapy with nintedanib / placebo for patients with advanced or recurrent endometrial cancer. not-yet-due
Listed as ongoing, but also has a completion date 2016-001848-20 A randomized, double-blind, placebo-controlled, phase II trial of Palbociclib in combination with Letrozole versus Placebo in combination with Letrozole for patients with Estrogen Receptor Positive ad... 2021-12-01 bad-data
Ongoing 2017-002805-36 NSGO-OV-UMB1; ENGOT OV30: A phase II umbrella trial in patients with relapsed ovarian cancer. Vaiheen II usean hoitohaaran tutkimus uusiutunutta munasarjasyöpää sairastavilla potilailla. not-yet-due
Reported results Terminated 2018-003756-20 A randomized double-blind placebo-controlled phase II trial of Rucaparib maintenance therapy for patients with locally advanced cervical cancer 2019-10-10 due-trials
Ongoing 2020-004738-39 ENGOT-OV56-NSGO-CTU-DOVACC. A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer. not-yet-due